Trial · NCT04304144
Participant flow28
How many started, completed or left each group, period by period.
21 to 28 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Continued Treatment Period | COMPLETED | Part A: CAEL101 500 mg/m^2 Combined With SoC CyBorD | 1 | |
| Continued Treatment Period | COMPLETED | Part A: CAEL101 750 mg/m^2 Combined With SoC CyBorD | 1 | |
| Continued Treatment Period | COMPLETED | Part A: CAEL101 1000 mg/m^2 Combined With SoC CyBorD | 4 | |
| Continued Treatment Period | COMPLETED | Part B: CAEL-101 Combined With SoC CyBorD and Daratumumab | 6 | |
| Continued Treatment Period | NOT COMPLETED | Part A: CAEL101 500 mg/m^2 Combined With SoC CyBorD | 3 | |
| Continued Treatment Period | NOT COMPLETED | Part A: CAEL101 750 mg/m^2 Combined With SoC CyBorD | 1 | |
| Continued Treatment Period | NOT COMPLETED | Part A: CAEL101 1000 mg/m^2 Combined With SoC CyBorD | 2 | |
| Continued Treatment Period | NOT COMPLETED | Part B: CAEL-101 Combined With SoC CyBorD and Daratumumab | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04304144/flow?page=2